Cargando…
Attack adjudication in neuromyelitis optica spectrum disorder: Substantiation of criteria by magnetic resonance imaging and biomarkers in N-MOmentum
BACKGROUND: The N-MOmentum trial investigated safety and efficacy of inebilizumab in participants with neuromyelitis optica spectrum disorder (NMOSD). OBJECTIVE: Evaluate the attack identification process and adjudication committee (AC) performance in N-MOmentum. METHODS: Adults (n = 230) with NMOSD...
Autores principales: | Weinshenker, Brian G, Wingerchuk, Dean M, Green, Ari J, Bennett, Jeffrey L, Kim, Ho Jin, Pittock, Sean J, Fujihara, Kazuo, Paul, Friedemann, Cutter, Gary, Marignier, Romain, Aktas, Orhan, Hartung, Hans-Peter, She, Dewei, Smith, Michael, Rees, William, Patterson, Kristina, Cimbora, Daniel, Katz, Eliezer, Cree, Bruce AC |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338695/ https://www.ncbi.nlm.nih.gov/pubmed/37282545 http://dx.doi.org/10.1177/13524585231172145 |
Ejemplares similares
-
Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder
por: Marignier, Romain, et al.
Publicado: (2021) -
Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder
por: Aktas, Orhan, et al.
Publicado: (2023) -
Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trial
por: Bennett, Jeffrey L., et al.
Publicado: (2022) -
Placebo-controlled study in neuromyelitis optica—Ethical and design considerations
por: Cree, Bruce AC, et al.
Publicado: (2015) -
Sensitivity analysis of the primary endpoint from the N-MOmentum
study of inebilizumab in NMOSD
por: Cree, Bruce AC, et al.
Publicado: (2021)